Sweden's Bonesupport Q4 revenue slightly misses expectations

BoneSupport Holding AB

24/02/2026 07:09

Overview

Swedish orthobiologics firm's Q4 revenue slightly missed analyst expectations

Company changed FDA application process for CERAMENT V to De Novo

Company entered share-swap agreement to secure performance shares

Outlook

Company did not provide specific future guidance

Result Drivers

US SALES GROWTH - US segment sales increased by 24%, contributing significantly to overall revenue growth

EUROW SALES GROWTH - Europe & Rest of the World segment saw a 13% sales increase, supporting overall revenue

FDA APPLICATION CHANGE - Company shifted CERAMENT V FDA application to De Novo process, affecting regulatory timeline

Company press release: ID:nMFN8HTGxm

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Slight Miss*
SEK 312.50 mln
SEK 313.25 mln (4 Analysts)
Q4 Adjusted EPS
SEK 0.67
Q4 Gross Margin
92.50%
Q4 EBIT
SEK 81.80 mln


*Applies to a deviation of less than 1%; not applicable for per-share numbers.

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)